key: cord-0738474-6gzdrti9
authors: Yates, Jennifer L.; Ehrbar, Dylan J.; Hunt, Danielle T.; Girardin, Roxanne C.; Dupuis, Alan P.; Payne, Anne F.; Sowizral, Mycroft; Varney, Scott; Kulas, Karen E.; Demarest, Valerie L.; Howard, Kelly M.; Carson, Kyle; Hales, Margaux; Ejemel, Monir; Li, Qi; Wang, Yang; Peredo-Wende, Ruben; Ramani, Ananthakrishnan; Singh, Gurpreet; Strle, Klemen; Mantis, Nicholas J.; McDonough, Kathleen A.; Lee, William T.
title: Serological Analysis Reveals an Imbalanced IgG Subclass Composition Associated with COVID-19 Disease Severity
date: 2021-06-15
journal: Cell Rep Med
DOI: 10.1016/j.xcrm.2021.100329
sha: 61ba18927888b7621148d7279824660c3a78b4a3
doc_id: 738474
cord_uid: 6gzdrti9

COVID-19 is associated with a wide spectrum of disease presentation, ranging from asymptomatic infection to acute respiratory distress syndrome (ARDS). Paradoxically, a direct relationship has been suggested between COVID-19 disease severity and the levels of circulating SARS-CoV-2-specific antibodies, including virus neutralizing titers. A serological analysis of 536 convalescent healthcare workers reveal that SARS-CoV-2-specific and virus-neutralizing antibody levels are elevated in individuals that experience severe disease. The severity-associated increase in SARS-CoV-2-specific antibody is dominated by IgG, with an IgG subclass ratio skewed towards elevated receptor binding domain (RBD)- and S1-specific IgG3. In addition, individuals that experience severe disease show elevated SARS-CoV-2 specific antibody binding to the inflammatory receptor FcɣRIIIa. Based on these correlational studies, we propose that Spike-specific IgG subclass utilization may contribute to COVID-19 disease severity through potent Fc-mediated effector functions. These results may have significant implications for SARS-CoV-2 vaccine design and convalescent plasma therapy.

The novel coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the 31 causative agent of COVID-19, a disease responsible for more than 2.6 million deaths in the span of 32

approximately one year. The case incidence based on virus detection estimates over 164 million cases 33 globally to date. However, if population-based serological surveys of SARS-CoV-2 are taken into 34 account, the infection rate of SARS-CoV-2 is likely much higher 1, 2 . This discrepancy highlights the 35 variability of COVID-19 disease presentation in the human population. The severity of disease caused 36 by SARS-CoV-2 infection ranges from an asymptomatic presentation, to acute respiratory distress 37 syndrome (ARDS), and death. Risk factors such as age, gender, and underlying disease are known to 38 be associated with COVID-19 disease severity; however, a subset of patients with severe disease are 39 younger without obvious comorbidities. The immunological features associated with severe COVID-19 40 disease include high levels of inflammatory cytokines, low lymphocyte counts, high neutrophil to 41 lymphocyte ratios, and increased serum proteins such as C-reactive protein (CRP), ferritin, and D-42 dimer 3-6 . In addition, several studies have shown that SARS-CoV-2-specific antibodies and neutralizing 43 titers are increased in patients who exhibit more severe disease 7-10 . Therefore, it is important to 44 consider that SARS-CoV-2 specific antibodies may play multiple roles in COVID-19 pathogenesis, 45 including control of viral infection, disease resolution, and immunopathology. 46

The humoral response to SARS-CoV-2 is primarily directed towards the viral nucleocapsid (N) protein 47 and the spike protein that decorates the surface of the virus. The N protein is an RNA binding protein 48 composed of an N-terminal RNA binding domain and a C-terminal oligomerization domain that are 49 essential for viral RNA transcription and replication 11 . The spike protein is a multi-domain trimeric 50 glycoprotein composed of two distinct subunits. The S1 subunit is composed of four domains, including 51 the receptor binding domain (RBD) of the spike glycoprotein 12 . The S2 domain forms the stalk-like 52 portion of the full-length trimeric protein and is responsible for viral fusion with the host cell membrane. 53

Antibody responses directed at the spike protein and RBD in particular have been identified as the main 54 J o u r n a l P r e -p r o o f

A total of 536 COVID-19 serum specimens from convalescent healthcare workers (HCW) were 74 received by the Wadsworth Center for SARS-CoV-2 serology testing. The sera were obtained from 75 individuals who had tested positive by RT-PCR and had illness consistent with SARS-CoV-2 infection. 76 Table 1 provides basic patient demographic information stratified by self-reported COVID-19 disease 77 severity. The gender distribution of the study cohort was biased towards females (29% male, 69% 78 female, with 2% gender unknown) reflecting the gender disparity within the HCW. The mean age and 79 days post-onset of symptoms (DPO) was roughly the same in all gender categories. Approximately 80 10% of the study cohort experienced severe disease, 40% moderate disease, 40% mild disease, and 81

10% with uncharacterized disease. The average age of each group in our cohort increased with 82 disease severity, as did the percentage of males within each group. In fact, the representation of males 83 (65%) in the severe group was more than double that of the mild group (31%), illustrating a clear 84 gender bias in COVID-19 disease severity (Table 1) . 85

Severity 87

Serum samples were assessed for SARS-CoV-2-specific antibodies using a clinical microsphere 88 immunoassay (MIA) to detect total antibody directed against N protein or RBD of SARS-CoV-2. We 89 used the median fluorescence intensity (MFI) of PE-labeled anti-human Ig to antigen-coupled beads as 90 a qualitative measure of SARS-CoV-2-specific antibody abundance in donor serum. "Cutoff" values for 91 each antibody isotype/antigen combination were defined as 3 standard deviations above the mean MFI, 92 as determined by a panel of 94 pre-COVID-19 (2009) human serum specimens. Clinically positive 93 antibody reactivity was defined as 6 standard deviations above the mean MFI (Emergency Use 94

Authorization: https://www.fda.gov/media/137541/download). We found that total serum antibody 95 (Figure 1a) . To evaluate the relationship between overall antibody levels and protective antibody we 97 measured viral neutralization using a plaque reduction neutralization test (PRNT) where the highest 98 dilution of sera providing 50% (PRNT50) or 90% (PRNT90) viral plaque reduction relative to a virus 99 only control was reported as the neutralizing titer. Both PRNT50 and PRNT90 measurements identified 100 a concomitant increase in virus neutralizing titers with disease severity (Figure 1b) . RBD-specific 101 responses were strongly correlated with virus neutralization, as revealed through a Spearman's 102 correlation analysis with PRNT90 values and MFI values. The correlation with PRNT90 titers was 103 greater for RBD-specific Ig than N-specific Ig (r = 0.68 and 0.53, respectively) (Figure 1c ). Since the 104 function of the RBD is host cell attachment through ACE-2 binding, our data suggests that the 105 neutralization activity of SARS-CoV-2-specific antibodies in our PRNT assay is primarily based on the 106 ability to block viral attachment and uptake by host cells [13] [14] [15] . 107

To better resolve the SARS-CoV-2 humoral immune response across COVID-19 severity groups, we 110 tested additional antibody isotypes and specificities in our clinical MIA assay. To normalize our antibody 111 measurements across antigens and isotypes, index value measurements were calculated by dividing 112 the raw MFI by the cut-off value (3 standard deviations) as determined by the average MFI from a panel 113 of pre-pandemic normal human serum specimens. In addition to N and RBD, we included the S1 and 114 S2 sub-unit domains as antibody targets, allowing us to incorporate all the potential epitopes from the 115 Spike protein, and to assess the contribution of each domain to the overall antibody response. In 116 general, we found that antibody reactivity to SARS-CoV-2 antigens differed dramatically between 117 isotypes. As expected, IgG was the dominant isotype generated in response to SARS-CoV-2 infection, 118

with antibodies from 97-98% of serum specimens yielding positive recognition of all antigens and 119 antigenic subunits tested (Figure 2a, Table S1 ,). IgM and IgA were primarily reactive towards the Spike specific IgM at this convalescent time-point is notable (~ day 40), as IgM is generally considered a 122 biomarker of acute-phase infection. IgM and IgA with specificity to the nucleocapsid were rare, with only 123 22% of specimens testing positive for each isotype, respectively. IgM antibodies with specificity for the 124 Spike S2 subunit were even more rare (5%), while IgA responses displayed a 36% positivity rate. As 125 shown in Figure 1 , we observed that total SARS-CoV-2-specific antibody increased with disease 126 severity. We next examined individual isotype distributions across disease categories. There was an 127 increase in IgG generated in the severe COVID-19 group as compared to mild, against all antigens 128 tested (N (1.3-fold, p<0.001); RBD (1.7-fold, p<0.0001); S1 (1.8-fold, p<0.0001); and S2 (1.7-fold, 129 p<0.0001)). In addition, IgM specific to the N-protein had a 1.6-fold increase in the severe group, as 130 compared to mild, with little or no change in other antigens. Finally, IgA generated against the N-protein 131 and the S1 subunit resulted in significant increases (2.4, p<0.0001, and 2.0, p=0.02, respectively) -the 132 largest fold changes observed between mild and severe disease categories (Figure 2b ; Table S2 ). 133

The significant increase in N-specific IgA is consistent with the observation that exceptionally high 134 levels of serum IgA were associated with acute respiratory distress syndrome (ARDS) 135 (https://doi.org/10.1101/2020.05.21.108308). Furthermore, the observed correlation of IgM and IgA 136 specific for the N-protein increasing with disease severity is reminiscent of the early N-dominated 137 response in deceased individuals reported by Atyeo et. al. 16 . Our results illustrate that while total 138 SARS-CoV-2 specific antibody levels increase with COVID-19 severity, this change is not equal among 139 antibody specificities or isotypes. The increase in total N-specific antibody and spike-specific IgG IgG3, and IgG4. Each subclass has unique properties and effector functions that are primarily driven by 147 the Fc portion of the antibody molecule including complement activation, Fc receptor (FcR) binding, and 148 serum half-life. In particular, the ability of an antibody to bind and signal through FcR on effector cells 149

can have profound effects on disease resolution in many models of infectious disease. Therefore, we 150 sought to characterize the IgG subclass usage of the SARS-CoV-2 antibody response. We found that 151

IgG1 and IgG3 were the dominant IgG subclasses produced in response to SARS-CoV-2 infection 152 ( Figure 3A) . The responses to nucleocapsid, RBD, and S1 subunit were each dominated by IgG1 with 153 over 90% of specimens testing positive (Table S3) . Strikingly, the IgG response toward the S2 subunit 154 was dominated by the IgG3 subclass with 94% of specimens yielding a positive clinical result. IgG2 155 responses were moderate, with a positivity rate ranging from 8 to 21%. Finally, IgG4 responses were 156 especially rare with a clinical positivity rate of 0 -9% ( Figure S1 , Table S3 ). Next, we asked whether 157 the IgG subclass representation changes in relation to COVID-19 disease severity. A small, yet 158 significant increase in N-specific IgG2 (1.5, p=0.002) was associated with disease severity, while RBD-159 specific IgG2 trended downward with disease severity ( Figure S1 , Table S4 ). We observed significant 160 increases in both IgG1 and IgG3 with increasing COVID-19 severity, specific for all antigens tested (N, 161 RBD, S1, and S2). The largest difference was seen with the IgG3-specific response toward the RBD 162 and S1 subunit with a 6.8-fold (p<0.0001), and 5.5-fold (p<0.0001) increases in the mean index ratio 163 between the mild and severe groups, respectively ( Figure 3B , Table S4 ). Together, these results 164 highlight distinct differences in the SARS-CoV-2 specific antibody profile among convalescent 165 individuals that experienced mild, moderate, or severe symptoms of COVID-19. 166

We sought to determine a minimal set of criteria that could best distinguish between individuals with 168 different disease severities without overfitting. A training subset of the data was used to create an initial 169 J o u r n a l P r e -p r o o f reactivities, gender, age, days post onset, and neutralizing antibody titers. Backwards stepwise 171 selection by Akaike information criterion (AIC) was performed on this model to determine the optimal 172 set of features. When this model's performance was measured on a testing subset of the data, it 173 displayed higher accuracy (60% , Table S5 ) than both the initial all-inclusive model and any individual 174 univariate model. The combined model that best discriminates between mild, moderate, and severe 175 COVID-19 includes age, RBD-specific IgG1, and S1-specific IgG3. As shown in Figure 4a , the severe 176 group clusters at high IgG1 RBD, IgG3 S1, and age measurements. In contrast, the mild and moderate 177 groups cluster toward lower IgG1 RBD, IgG3 S1, and age measurements. In order to account for the 178 confounding effects of age, a similar series of ordered probit regression models were created that 179 included age as a covariate. All variables that were significantly associated with disease severity in the 180 previous models retained their significant association with disease severity except S2-specific IgG1 181 (Table S6) . 182

Based on the results of the ordered probit regression model, we sought to define the relative 183 contribution of both IgG1 and IgG3 to the overall SARS-CoV-2-specific pool of IgG. To this end, we 184 calculated a ratio based on the index value of each IgG subclass divided by the total IgG index value of 185 the same antigen (IgG subclass /IgG total ). No change was observed in N-specific IgG1 and IgG3 subclass 186 ratios between COVID-19 disease severity groupings. We detected modest, yet significant increases in 187 the IgG1 subclass ratio to both the S1 and S2 subunits between mild and severe groups (1.4-fold, 188 p=0.0002 and 1.9-fold, p=0.0004, respectively). A pronounced increase with the RBD-specific and S1 189 specific IgG3 subclass ratios was identified with increasing COVID-19 disease severity. Specifically, we 190 measured 3.3-fold (p=0.005) and 3.4-fold (p=0.002) increases in the RBD-specific IgG3 subclass ratio 191 between the moderate and severe groups as compared to the mild group. We also measured a 2.2-fold 192 increase in the S1-specific IgG3 subclass ratio between the moderate and severe groups (p=0.0002) 193 and the mild and severe groups (p<0.0001) (Figure 4b , Table S7 ). 194 COVID-19 patients hospitalized due to the severity of their condition and were clinically positive for 196 RBD-specific IgG. All serum samples were acquired at time of hospital admission (Table S8 ). The 197 optimal three variable ordered probit model predicted COVID-19 disease severity with 34.4% accuracy 198 (95% CI 0.186, 0.532). The low predictive value of our model when tested on the VC is likely due to the 199 sampling timepoint (convalescent versus acute), and significantly lower levels of IgG ( Figure S3 ). In 200 contrast, when we compared the RBD-and S1-specific index ratios of the VC to the convalescent 201 cohort we observed similar results. The mean IgG3 index ratio specific to the RBD (0.666) of the 202 validation cohort was similar to the severe group (0.544), with a 2.7-fold increase (p=0.004) over the 203 mild group. Furthermore, the mean IgG3 subclass ratio of the VC specific to the S1 subunit (1.103) was 204 significantly higher than all groups in the HCW cohort with a 4.8-fold increase (p<0.0001) over the mild 205

group. In addition to high IgG3 index ratios to the spike proteins, we also observed significant increases 206 in the IgG1 index ratio for the spike protein (RBD, S1, and S2), with 1.9 (p<0.0001), 3.8 (p<0.0001), 207 and 3.8-fold (p<0.0001) increases, respectively. These data highlight the utility of using index ratios 208

where the IgG subclass is normalized to the level of total IgG and can be used across various stages 209 during disease. In summary, these data show that a disease severity-associated increase in total 210

Spike-specific IgG is accompanied by a proportional increase of IgG3 within the antibody pool. 211

A correlation network was created to examine the relationship between antibody isotypes, subclasses, 213 antigen specificity, viral neutralization, and clinical features of the HCW dataset. The network was 214 based on a comprehensive correlation matrix (Figure S2) , and stringently gated on only the strongest 215 associations with a Spearman's coefficient above 0.65. As expected, S1 and RBD measurements were 216 highly correlated, as were IgG and corresponding IgG subclasses. A dominant network cluster was 217 formed between N-specific IgG, S1-specific IgG (including the RBD domain), and viral neutralizing titers 218 ( Figure 5 ). N-specific IgG/IgG1/IgG3 formed its own mini-cluster on the edge of the highly inter-related 219 J o u r n a l P r e -p r o o f correlated with each other (r s = 0.848), and the PRNT90 measurement was strongly correlated (0.5 ≤ r s 221 ≤ 0.7) with IgG, IgG1, antibodies targeting the S1 domain and RBD of the spike protein. This cluster 222 was also significantly correlated with disease severity, as determined by ordered probit regression 223 (Table S5) . IgM, IgA, and IgG2 responses to S1 and RBD were also highly correlated yet separate from 224 the central cluster. Taken together, our results reveal a shift in the proportional Spike-specific IgG 225 response toward the highly inflammatory IgG3 subclass 18 that is linked to COVID-19 disease severity, 226

and not with increases in viral neutralizing activity. 227

To demonstrate a functional relationship between proportional IgG subclass differences and disease 229 severity, we developed a Spike-specific microsphere-based FcR binding assay (STAR methods). human serum specimens showed minimal CD16a binding to FL-Spike bound serum. In contrast, we 237 detected a robust CD16a binding signal from COVID-19 patients, which included 43 randomly selected 238 specimens from the mild HCW group, all 49 specimens from the severe HCW group, and the 32 VC 239 specimens. We detected significantly increased FL-Spike-specific CD16a binding in the severe (3.2-fold 240 p=0.0009) and VC (2.9-fold p=0.001) groups, as compared to the mild group (Figure 6a) . Pearson's 241 correlation analyses revealed strong, significant correlations between both S1-specific IgG1 and IgG3 242

with CD16a binding in all groups. In general, levels of IgG1 were better correlated with CD16a binding 243 than IgG3 (Figure 6b) . This difference was most noticeable in the "mild" group where r p = 0.79 for IgG1, 244 and r p =0.53 for IgG3, which is likely due to the low levels of IgG3 in this group. In conclusion, the 245 increased CD16a binding that we observed in the severe group and hospitalized validation cohort 246 reveals a potential inflammatory component of the SARS-CoV-2 antibody response that correlates with 247 COVID-19 disease severity. In the present study, we performed a comprehensive analysis of the serum antibody response to 263 SARS-CoV-2 in a cohort of 536 recovered HCW who experienced varying degrees of COVID-19 264 severity. In general, we found that age, total SARS-CoV-2-specific antibody, and viral neutralizing 265 activity was increased in individuals who experienced severe disease. The serological profile for those 266 who experienced severe COVID-19 was characterized by both a global increase in N-specific 267 antibodies, as well as an increase in spike-specific IgG, and SARS-CoV-2 neutralizing titers. 268

Paradoxically, high-titer neutralizing antibodies are known to be protective and a biomarker of immunity 269 J o u r n a l P r e -p r o o f neutralization, and increased disease severity we performed a thorough analysis of the IgG subclass 271 response to SARS-CoV-2. Our analysis revealed a substantial difference in the spike-specific IgG 272 subclass composition, where a greater proportion of S1 and RBD-specific IgG3 were associated with 273 COVID-19 severity in both a convalescent and acutely ill hospitalized cohort. Further analyses of the 274 convalescent cohort found that Spike-specific IgG1 and not IgG3 was most closely correlated with in 275 vitro viral neutralization. Moreover, those with severe disease (including the validation cohort of 276 hospitalized patients) showed increased spike-specific binding to FcɣRIIIa as compared to patients who 277 experienced mild disease. Together, our data suggest that excess IgG3 may play an inflammatory role 278 in the pathogenesis of COVID-19 in some individuals. Therefore, we hypothesize that an unbalanced 279

IgG response enriched in inflammatory subclasses may promote excess inflammation, exacerbating the 280 pathology of An explanation for the overall increase in SARS-CoV-2 specific antibody in severe patients is simply 282 and ADCD have been correlated with COVID-19 survival, spike-specific antibodies that promoted Fc-297 mediated NK cell activities were expanded in non-survivors 16 -highlighting the potential role for 298

FcɣRIIIa-mediated functions in pathologic inflammation in severe COVID-19. Our data supports this 299 observation, as FcɣRIIIa is the only Fc receptor expressed on NK cells, and has heightened affinity for 300

IgG3. There is precedence for antibody/FcɣRIIIa-mediated inflammation causing detrimental effects in 301 other viral infections. For example, secondary Dengue virus infection can lead to Dengue hemorrhagic 302 fever or Dengue shock syndrome through antibody-dependent enhancement, where the presence of 303 afucosylated IgG1 and FcɣRIIIa engagement was shown to be predictive of disease severity 30 . In the 304 context of these data, it is tempting to speculate that an increased proportion of spike-specific IgG3 305 may be predictive of long-term COVID-19 symptoms frequently seen during SARS-CoV-2 306

convalescence. Further studies are needed to address the true contribution of IgG subclasses and Fc 307 effector functions to COVID-19 disease resolution or pathology. While recent data suggests that ADCD 308 plays a protective role in COVID-19 16 , antibody-dependent pathways should not be ruled out as a 309 potential driver of inflammation and disease pathology 31 . In conclusion, we recommend that the 310 potential contribution of S1 and RBD-specific IgG3 to COVID-19 disease severity should be a strong 311 consideration for SARS-CoV-2 vaccine design, monoclonal antibody therapeutics, and convalescent 312 plasma therapy. 313

The convalescent time-point at which this study was conducted allowed us to capture a large cohort 315 that was with well associated disease severity classifications. The size of our patient cohort enabled a 316 robust analysis of the antibody response to SARS-CoV-2 in individuals with self-reported mild, 317 moderate, or severe disease. However, self-reporting disease severity can be subjective and may 318 contribute to some overlap seen between the severity groupings. The late time-point (day 40 post 319 addition, samples from the full spectrum of COVID-19 presentation, including asymptomatic individuals 321 and non-survivors would significantly strengthen our study. Overall, this study is correlational, and 322 would be strengthened by additional, and comprehensive functional studies. 323

We acknowledge and thank the members of the following Wadsworth Center laboratories and core 

The authors declare no competing interests. Index values for the IgM, IgA, and IgG reactivity to SARS-CoV-2 antigens separated by COVID-19 368 disease severity (n=481). Statistical significance was determined by the non-parametric Kruskal-Wallis 369 test where *p < 0.05 **p < 0.001 ***p < 0.0001, and ****p < 0.00001 adjusted for multiple comparisons 370 by Dunn's test. See also Supplemental Table 2 . 371

Across COVID-19 Disease Severities. Serum specimens from convalescent COVID-19 donors were 373 analyzed for reactivity of IgG1, and IgG3 specific to the SARS-CoV-2 nucleocapsid, RBD, S1 subunit, 374 or S2 subunit. Index values represent the raw MFI divided by the cutoff value (3 standard deviations 375 above the mean) determined by the average MFI of a panel of 94 pre-pandemic normal human serum 376 specimens (cutoff = dashed line). (a) Reactivity of IgG1, IgG2, and IgG3 to SARS-CoV-2 nucleocapsid, 377 RBD, S1 subunit, or S2 subunit of the full patient cohort (b) or grouped by disease severity. Index value 378

represents the raw MFI divided by the background cutoff value determined by a panel of 94 normal 379 human serum specimens. Statistical significance was determined by the non-parametric Kruskal-Wallis 380 test where *p < 0.05 **p < 0.001 ***p < 0.0001, and ****p < 0.00001 adjusted for multiple comparisons 381 by Dunn's test. See also Supplemental Figure 1 and Supplemental Table 4 . 382

dimensional scatter plot depicting the optimal feature set of disease severity-associated features (age, 384 log10-transformed index values (MFI/cutoff) for S1-specific IgG3, and RBD-specific IgG1) as 385 determined by ordered probit regression and backwards stepwise selection by Akaike information 386 criterion. Data is displayed as the distribution of mild (yellow), moderate (orange), and severe (red) 387 disease severities across variables in 478 patients. (b) Serum sample index ratios for IgG1 and -3 388 specific to the N, RBD, S1, and S2 subunits were calculated by dividing the IgG subclass index value 389 by the paired total IgG index value (IgG subclass /IgG total ) for each antigen. Index ratios were grouped by 390 disease by disease severity (n=481). Statistical significance was determined by the non-parametric 391

Kruskal-Wallis test where *p < 0.05 **p < 0.001 ***p < 0.0001, and ****p < 0.00001 adjusted for multiple 392 comparisons by Dunn's test. See also Supplemental Tables 5,6, and 7. 393 an antibody targeting the nucleocapsid (orange), S1 (blue), S2 (green), or RBD (grey) regions, or to 398 neutralizing antibody titers (pink). Black borders around nodes correspond to variables with a significant 399 correlation with severity determined by ordered probit regression modeling, while controlling for age as 400 a confounding variable. All displayed correlations are statistically significant (Benjamini and Hochberg 401 adjusted p < 0.05). MFI of the entire data set. (c) Spearman's correlation coefficient comparing the IgG 402 response to the PRNT90 neutralizing titer. See also Figure S2 . 403 MFI of CD16a binding to the log 10 transformed MFI of S1-specific IgG1 or IgG3. 410 J o u r n a l P r e -p r o o f

Further information and requests for resources and reagents should be directed to the lead contact, Dr. 418

William Lee (william.lee@health.ny.gov). 419

Resources used in this study will be made available to the scientific community upon request, and 421

following execution of a material transfer agreement, by contacting Dr. William Lee 422 (william.lee@health.ny.gov). 423

The amino-acid sequence of the SARS-CoV-2 S glycoprotein sequence can be found on GenBank 425 (MN908947). All other data generated are included in figures and tables in this published article. 426

Studies were performed on sera from 536 clinical specimens submitted to the Wadsworth Center, New 430

York State Department of Health for determination of antibody reactivity to SARS-CoV-2. The study 431 population were recovered individuals who were all RT-PCR confirmed by Roche COVAS 6800 or 432

Cepheid XPert for the presence of SARS-CoV-2 and who had a self-reported degree of disease 433 severity (mild, moderate, or severe). All individuals had recovered from the disease and had defined 434 days between the onset of symptoms and sample collection. Specimens were stored at 4°C until 435 clinical tested was completed (>1 week) and transferred to -80°C for long-term storage. Aliquots were 436 made to minimize freeze-thaw. All testing and archiving of human specimens was approved by 437 NYSDOH Institutional Review Board (IRB 20-021). See also Table 1 . 438

The validation cohort included sera from 32 acute COVID-19 patients who were admitted to Albany 441

Medical Center between October 2020 and January 2021. All patients had a positive for SARS-CoV-2 442 test result upon admission. All patients were hospitalized because of the severity of their illness as 443 determined by their clinician with demographic data as reported in Table S8 . Specimens were 444 processed on the same day of collection and placed into -80C freezer for long term storage. The study 445 was approved by the IRB at Albany Medical Center (protocol # 5929); all patients provided written 446 informed consent. 447

The amino-acid sequence of the SARS-CoV-2 S glycoprotein sequence (GenBank: MN908947) were 451 used to design a codon-optimized version for mammalian cell expression. The synthetic gene encoding 452 the receptor binding domain (RBD) a.a.319-541)) and S1 subunit (a.a.1-604) of the S glycoprotein 453 were cloned into pcDNA 3.1 Myc/His in-frame with c-Myc and 6-histidine epitope tags that enabled 454 detection and purification. The cloned genes were sequenced to confirm that no errors had 455 accumulated during the cloning process. All constructs were transfected into Expi293 cells using 456

ExpiFectamine 293 Transfection Kit (Thermo Fisher). Recombinant proteins were purified by 457 immobilized metal chelate affinity chromatography using nickel-nitrilotriacetic acid (Ni-NTA) agarose 458 beads, eluted from the columns using 250 mmol/L imidazole, and then dialyzed into phosphate-buffered 459 saline (PBS), pH 7.2. Proteins were checked for size and purity by sodium dodecyl sulfate 460 polyacrylamide gel electrophoresis (SDS-PAGE). 461

The stabilized trimer ectodomain of the SARS-CoV-2 spike glycoprotein sequence (GenBank: 462 protease cleavage site, a TwinStrepTag and an 8x HisTag. The construct was cloned into the 465 mammalian expression vector pcDNA3.1. The construct was then transfected into Expi293 cells using 466 the ExpiFectamine Transfection Kit (ThermoFisher). Protein was purified using StrepTactin resin (IBA) 467 followed by size-exlusion chromatography using a Superose 6 10/300 column (GE Healthcare). Resources, NR-52281) and incubated for 1 h at 37°C, 5% CO 2 . The virus:serum mixture (100µl) was 493 applied to VeroE6 cells grown to 95-100% confluency in 6 well plates. Adsorption of the virus:serum 494 mixture was allowed to proceed for 1 hour at 37°C, 5% CO 2. Following the adsorption period, a 0.6% 495 agar overlay prepared in cell culture medium (Eagle's Minimal Essential Medium, 2% heat inactivated 496 FBS, 100µg/ml Penicillin G, 100 U/ml Streptomycin) was applied. Two days post-infection, a second 497 agar overlay containing 0.2% neutral red prepared in cell culture medium was applied, and the number 498 of plaques in each sample well were recorded after an additional 1-2 days incubation. Neutralizing titers 499

were defined as the inverse of the highest dilution of serum providing 50% (PRNT50) or 90% (PRNT90) 500 viral plaque reduction relative to a virus only control. This assay has been described and is considered 501 the standard for determination of neutralizing virus-specific antibody titers [33] [34] [35] . 502

Subjects with known disease severity and gender were included in ordered probit regression analysis. 505

The data was randomly separated into training (70%) and testing (30%) subsets. Data was then 506 centered by subtracting the mean of each predictor from that predictor's values, and then scaled by 507 dividing by the standard deviation. Imputation of missing values was performed using the k-nearest 508 neighbors algorithm. Each created model's accuracy was assessed by measuring its performance on 509 the testing subset of data. One-sided binomial tests were performed to determine if the accuracy of 510 each model was significantly better than the no-information rate. Variable selection for the final model 511 was performed by backwards stepwise selection by Akaike information criterion.

Spearman's correlations were calculated using all complete pairs of variables in the dataset. All 514 associated p-values were then adjusted via the Benjamini and Hochberg method. The network created 515 using these Spearman's correlations was gated to only include those relationships with an r s > 0.65. 516

Eigenvector centrality was calculated for each variable and is represented by the size of the respective 517 node. Edge width corresponds with the strength of each correlation. R version 4.0.2 was used for the 518 probit regression modeling and construction of the correlation matrix (R Core Team (2020). R: A 519 language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, 520

Austria. URL https://www.R-project.org/.). The caret, MASS, and RANN packages were also used for 

High Community SARS-CoV-2 Antibody Seroprevalence in 535 a Ski Resort Community

Prevalence of SARS-CoV-2 in

ENE-COVID): a nationwide, population-based seroepidemiological study

Deep immune profiling of COVID-19 patients reveals 542 distinct immunotypes with therapeutic implications

Comprehensive mapping of immune perturbations 545 associated with severe COVID-19

Clinical and immunological features of severe and moderate coronavirus disease 2019

Complex Immune Dysregulation 551 in COVID-19 Patients with Severe Respiratory Failure

Antibody responses to SARS-CoV-2 in patients with COVID-19

Mapping Neutralizing and Immunodominant Sites on the

SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology

Spike-561 specific circulating T follicular helper cell and cross-neutralizing antibody responses in COVID-19-562 convalescent individuals

Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential 568 unique drug targeting sites

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Convergent antibody responses to SARS-CoV-2 in convalescent 574 individuals

Rapid Generation of Neutralizing 577

Antibody Responses in COVID-19 Patients

Human 579 monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting 580 enzyme 2 receptor

Distinct Early Serological Signatures Track with SARS-CoV-2 Survival

Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality

IgG subclasses and allotypes: from structure to 588 effector functions. Front Immunol 5, 520. 2014/11/05. 589 19

Beyond binding: antibody effector 595 functions in infectious diseases

Polyfunctional Fc-effector profiles mediated by IgG subclass 598 selection distinguish RV144 and VAX003 vaccines

Antibody Fc effector functions and IgG3 associate with decreased

HIV-1 risk

IgG subclass distribution of antibodies to 603 bacterial and viral antigens

Novel correlates of protection against pandemic H1N1 influenza A 606 virus infection

Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS

Proinflammatory IgG Fc structures in patients with 614 severe COVID-19

Afucosylated IgG characterizes enveloped viral responses and 617 correlates with COVID-19 severity

IgG antibodies to dengue enhanced 620 for FcgammaRIIIA binding determine disease severity

Complement in immune and inflammatory disorders: 622 pathophysiological mechanisms

A Multiplex 624

Microsphere Immunoassay for Zika Virus Diagnosis

Antigenic relationships between flaviviruses as determined by cross-neutralization tests 629 with polyclonal antisera

Development of a High-Throughput Respiratory Syncytial Virus Fluorescent Focus-Based 632

Fc effector functions, and inflammation characteristic of severe COVID-19